AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01404767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
Study NCT01352390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
Study NCT01404767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
Study NCT01709825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Bifidobacterium Bifidum
Description: Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
Study NCT01709825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
Study NCT01709825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Lactobacillus helveticus
Description: Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
Study NCT04019691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mix-and-Match
Description: Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
Study NCT04019691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDOF
Description: Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
Study NCT01709825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic- Bifidobacterium longum ss. Infantis R0033
Description: Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
Study NCT04413786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin treatment
Description: intranasal administration of oxytocin (24IU)
Study NCT04413786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: intranasal administration of placebo (24IU)
Study NCT01942993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
Study NCT02317003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention PPIL
Study NCT02317003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control OR
Study NCT03867240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients \<50 kg and 200 mg for patients > 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
Study NCT03867240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
Study NCT03526068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeZoneUVC
Description: SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
Study NCT02764593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 targeted immunotherapy
Study NCT02764593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Anti-cancer alkylating agent
Study NCT01314131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulation group
Description: Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~* a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~* an interest questionnaire for patients. It contains 40 questions about activities.~* the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement .
Study NCT04030026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL ER
Description: Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period.
Study NCT04030026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
Study NCT04019691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal
Description: Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
Study NCT01678378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP Intervention
Description: Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
Study NCT00991653 — intervention group
Intervention type: PROCEDURE
Intervention: Fasting blood sample.
Description: Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
Study NCT04663503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Depending on the age, there will be two components of the exercise program completed by the patients. The first component will be strengthening exercises. The second component will be endurance activities. This will be administered by the physical therapist
Study NCT00855244 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic exams
Description: Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
Study NCT03810196 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
Description: Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
Study NCT02539901 — intervention group
Intervention type: BEHAVIORAL
Intervention: Evaluation of the detection of non-linguistic sounds
Description: Evaluation of the detection of non-linguistic sounds (sound room)
Study NCT02539901 — intervention group
Intervention type: BEHAVIORAL
Intervention: Free hearing test categorization
Description: Free hearing test categorization evaluation
Study NCT02539901 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early Social Communication Scale (ECSP)
Description: Early Social Communication Scale (ECSP) evaluation
Study NCT02539901 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychomotor infancy development scale
Study NCT02539901 — intervention group
Intervention type: BEHAVIORAL
Intervention: NEPSY (two domains: memory and learning and attention and executive functions).
Description: NEPSY evaluation
Study NCT02191371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
Study NCT02191371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
Study NCT02264340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique Autogenic Training
Description: Autogenic Training
Study NCT02264340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined treatment Autogenic Training + Cervical exercises and postural correction
Description: Autogenic Training + Cervical exercises and postural correction
Study NCT00524901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
Study NCT00524901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
Study NCT03264573 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell
Description: after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
Study NCT03264573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSCs
Description: manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
Study NCT01826006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser
Study NCT01826006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Thrombus Aspiration
Study NCT04632134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (tVNS)
Description: Transcutaneous vagal nerve stimulation (tVNS) will be performed using a noninvasive battery powered Transcutaneous Electrical Nerve Stimulation device (Nemos ©; Cerbomed, Germany). Electrical stimulation will be delivered by external electrodes through the skin surface at the conca of right external ear. Electrical current will be applied continuously with a pulse width of 200 μs and pulse frequency of 25 Hz. Stimulation amplitude will be adjusted between 0.1-6 mA, to a maximal amplitude level without causing patient discomfort.
Study NCT04632134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tVNS electrodes will be positioned in the right ear of the POTS patients without delivering stimulus (Sham)
Study NCT04632134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home daily transcutaneous vagal nerve stimulation
Description: The home stimulation will consist of 4 hours of stimulation by the tVNS device organized as a 4 sessions of 1 hour. The home stimulation will last for 14 consecutive days.
Study NCT04260594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbidol
Description: Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
Study NCT03615950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone Mineral Density (DEXA) scan
Description: Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
Study NCT04260594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: basic treatment
Study NCT04260594 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: basic treatment
Description: basic treatment
Study NCT04156438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low tidal volume ventilation
Description: Conventional ventilation strategy for patient with ARDS
Study NCT04156438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway pressure release ventilation
Description: Experimental ventilation protocol for patients with ARDS
Study NCT04380662 — intervention group
Intervention type: OTHER
Intervention: Risk factors
Description: The studied potential risk factors will be the following:~* Socio-demographic: age, sex, place of residence, CSP and income.~* Comorbidities or aggravation: COPD, asthma, immunosuppression, or heart failure, diabetes imbalance, etc.~* Clinical signs: asthenia, dyspnea (kinetics), blood sugar, nutritional status, weight gain...~* Drugs other than those related to the infection and potential self-medication (anti-inflammatory, CEI, ARA...)
Study NCT03866811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Erica
Description: The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
Study NCT03615950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Measurement
Description: Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
Study NCT01445015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management program
Description: 10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
Study NCT01445015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer viewed movies
Description: PG rated movies to be viewed over 10 sessions in peer setting
Study NCT02554084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Digital images of tear film
Study NCT02554084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Digital images of tear film
Study NCT02048527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global
Description: Single medium for the culture of embryos from Day1 to Day 5
Study NCT02048527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Origio
Description: Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
Study NCT02267616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel Implant
Description: Subdermal arm implant
Study NCT02267616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel Implant
Description: Subdermal arm implant
Study NCT01950052 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet group 800 Kcal diet
Description: Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
Study NCT01073176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAMS (Training Attention Executive and Motor Skills)
Description: Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
Study NCT04281121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3 fatty acids
Description: : Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals
Study NCT01352871 — intervention group
Intervention type: BEHAVIORAL
Intervention: Concentration / meditation
Description: from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
Study NCT01352871 — intervention group
Intervention type: DRUG
Intervention: lipopolysaccharide
Description: lipopolysaccharide 2ng/kg intravenously
Study NCT03710681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Study NCT02401724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT02401724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Training
Study NCT02401724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Training
Study NCT04908696 — intervention group
Intervention type: PROCEDURE
Intervention: routines
Description: For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery (CO2 laser resection), open partial laryngectomy (vertical partial laryngectomy, cricohyoidoepiglottopexy, cricohyoidopexy, horizontal partial laryngectomy), partial hypopharyngectomy, radiotherapy, and transoral robotic surgery were performed for patients with proper indications (NCCN 2020).~For advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, concurrent chemoradiotherapy, neoadjuvant therapy + radiotherapy/chemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy were performed for patients with proper indications (NCCN 2020).
Study NCT05573425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene gel 0.1%
Description: Tazarotene gel 0.1% applied daily on Acne Scars.
Study NCT05573425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: Microneedling via dermaroller device performed on Acne Scars monthly.
Study NCT04381117 — intervention group
Intervention type: DRUG
Intervention: Previously Treated with EN3835
Description: No treatment to be administered - Observational only
Study NCT01553708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor with silver sulfadiazine cream
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Study NCT01553708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver zinc sulfadiazine cream
Description: Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
Study NCT04859959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gallium-68 Pentixafor PET/CT
Description: Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.
Study NCT01813786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 2
Description: Focusing energy on skin
Study NCT01813786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 1
Description: focusing energy at skin surface
Study NCT01813786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with handpiece 3
Description: Focusing energy on skin